<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04993222</url>
  </required_header>
  <id_info>
    <org_study_id>HC1507YBE201901</org_study_id>
    <nct_id>NCT04993222</nct_id>
  </id_info>
  <brief_title>A Pilot Bioequivalence Study Between Amphotericin B Liposome for Injection and AmBisome® in Healthy Subjects</brief_title>
  <official_title>A Randomized, Open-label, Two-preparation, Single-dose, Two-sequence Pilot Bioequivalence Study Between Amphotericin B Liposome for Injection and AmBisome® in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The 2 × 2 crossover designed study is to evaluate the bioequivalence of two different&#xD;
      amphotericin B liposome for injection after single IV infusion at the same dose in normal&#xD;
      healthy subjects.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 4, 2020</start_date>
  <completion_date type="Actual">November 16, 2020</completion_date>
  <primary_completion_date type="Actual">September 8, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bioequivalence based on Cmax</measure>
    <time_frame>predose, 0.5, 1.0, 1.5, 2.0,2.25,2.5,3.0,4.0,6.0,8.0,10.0,14.0,26.0,50.0,74.0,146,218,290,362,434,506,578,674 hours after intravenous infusion</time_frame>
    <description>90% CI of Cmax of liposome-encapsulated and non-liposome-encapsulated Amphotericin B between Amphotericin B liposome for injection and AmBisome® within 80.00%~125.00%.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Bioequivalence based on AUC0-t</measure>
    <time_frame>predose, 0.5, 1.0, 1.5, 2.0,2.25,2.5,3.0,4.0,6.0,8.0,10.0,14.0,26.0,50.0,74.0,146,218,290,362,434,506,578,674 hours after intravenous infusion</time_frame>
    <description>90% CI of AUC0-t of liposome-encapsulated andnon-liposome-encapsulated Amphotericin B between Amphotericin B liposome for injection and AmBisome® within 80.00%~125.00%.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Bioequivalence based on AUCinf</measure>
    <time_frame>predose, 0.5, 1.0, 1.5, 2.0,2.25,2.5,3.0,4.0,6.0,8.0,10.0,14.0,26.0,50.0,74.0,146,218,290,362,434,506,578,674 hours after intravenous infusion</time_frame>
    <description>90% CI of AUC0-∞ of liposome-encapsulated and non-liposome-encapsulated Amphotericin B between Amphotericin B liposome for injection and AmBisome® within 80.00%~125.00%.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tmax of liposome-encapsulated and non-liposome-encapsulated Amphotericin B</measure>
    <time_frame>predose, 0.5, 1.0, 1.5, 2.0,2.25,2.5,3.0,4.0,6.0,8.0,10.0,14.0,26.0,50.0,74.0,146,218,290,362,434,506,578,674 hours after intravenous infusion</time_frame>
    <description>Time of maximum observed concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2 of liposome-encapsulated and non-liposome-encapsulated Amphotericin B</measure>
    <time_frame>predose, 0.5, 1.0, 1.5, 2.0,2.25,2.5,3.0,4.0,6.0,8.0,10.0,14.0,26.0,50.0,74.0,146,218,290,362,434,506,578,674 hours after intravenous infusion</time_frame>
    <description>Terminal elimination half-life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>λz of liposome-encapsulated and non-liposome-encapsulated Amphotericin B</measure>
    <time_frame>predose, 0.5, 1.0, 1.5, 2.0,2.25,2.5,3.0,4.0,6.0,8.0,10.0,14.0,26.0,50.0,74.0,146,218,290,362,434,506,578,674 hours after intravenous infusion</time_frame>
    <description>Apparent elimination rate constant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Residual area of liposome-encapsulated and non-liposome-encapsulated Amphotericin B</measure>
    <time_frame>predose, 0.5, 1.0, 1.5, 2.0,2.25,2.5,3.0,4.0,6.0,8.0,10.0,14.0,26.0,50.0,74.0,146,218,290,362,434,506,578,674 hours after intravenous infusion</time_frame>
    <description>Extrapolated area</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of treatment-emergent adverse events for the test and the reference products</measure>
    <time_frame>predose, 0.5, 1.0, 1.5, 2.0,2.25,2.5,3.0,4.0,6.0,8.0,10.0,14.0,26.0,50.0,74.0,146,218,290,362,434,506,578,674 hours after intravenous infusion</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Bioequivalence</condition>
  <arm_group>
    <arm_group_label>Sequence TR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6 healthy subjects assigned to the sequence TR were administrated intravenously for 120 mins with the test product of amphotericin B liposome for injection in period 1 and the reference product of AmBisome® in period 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence RT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6 healthy subjects assigned to the sequence RT were administrated intravenously for 120 mins with the reference product of AmBisome® in period 1 and the test product of amphotericin B liposome for injection in period 2.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amphotericin B liposome for injection</intervention_name>
    <description>IV infusion</description>
    <arm_group_label>Sequence RT</arm_group_label>
    <arm_group_label>Sequence TR</arm_group_label>
    <other_name>the test product</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AmBisome®</intervention_name>
    <description>IV infusion</description>
    <arm_group_label>Sequence RT</arm_group_label>
    <arm_group_label>Sequence TR</arm_group_label>
    <other_name>the reference product</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subjects fully understand and voluntarily participate in this study and sign informed&#xD;
             consent.&#xD;
&#xD;
          2. Healthy female and male volunteers aged 18-55 years.&#xD;
&#xD;
          3. Body weight ≥ 50 kg for male and ≥ 45 kg for female with a body mass index (BMI) in&#xD;
             the range of 19.0 to 26.0 kg/m2 (inclusive).&#xD;
&#xD;
          4. Subjects must be in good health on the basis of medical history, physical examination,&#xD;
             electrocardiogram, chest X-ray, and routine laboratory evaluations.&#xD;
&#xD;
          5. Able to communicate well with the investigator and comply with the requirements of the&#xD;
             study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of allergic reactions to amphotericin B or its analogs. History of allergy to&#xD;
             two or more kinds of drugs or food.&#xD;
&#xD;
          2. Subjects have any history of surgery, trauma that may affect the safety of the study&#xD;
             or the intracorporal process of the drug, or have a surgical schedule during the study&#xD;
             period.&#xD;
&#xD;
          3. Use of any prescription or over the counter medication within 14 days prior to&#xD;
             screening.&#xD;
&#xD;
          4. History of drug abuse within 6 months prior to screening.&#xD;
&#xD;
          5. Smoking more than 5 cigarettes per day within 3 months prior to screening, or unable&#xD;
             to stop using any tobacco products during the trial period.&#xD;
&#xD;
          6. Consumption of alcohol in excess of 14 units/week within 3 months prior to screening.&#xD;
&#xD;
          7. Consumption excessive amounts of tea, coffee and/or caffeine-rich beverages daily&#xD;
             within 3 months prior to screening.&#xD;
&#xD;
          8. Participation in other trial within 3 months prior to screening.&#xD;
&#xD;
          9. Donation or loss of more than 400 mL blood within 3 months prior to screening.&#xD;
&#xD;
         10. Subject (female) is lactating or pregnant.&#xD;
&#xD;
         11. Subject who cannot tolerate venipuncture or have a history of needle and blood&#xD;
             sickness.&#xD;
&#xD;
         12. Subject who has special requirements on diet and cannot accept the uniform diet.&#xD;
&#xD;
         13. Subject who has childbearing plan, unwillingness or inability to use effective&#xD;
             contraceptives from 2 weeks before the screening to 6 months after the last dosing of&#xD;
             the study drug.&#xD;
&#xD;
         14. Any positive test result for Hepatitis B surface antigen, hepatitis C virus antibody,&#xD;
             anti-human immunodeficiency virus antibody or anti-syphilis spirochete.&#xD;
&#xD;
         15. Female subjects with positive pregnancy test results during the screening period or&#xD;
             during the study.&#xD;
&#xD;
         16. Positive test result for alcohol screening or drug abuse.&#xD;
&#xD;
         17. AST or ALT, total or direct bilirubin, alkaline phosphatase and creatinine are above&#xD;
             the upper limit of normal and potassium is below the lower limit of normal; any other&#xD;
             abnormalities in laboratory tests and ancillary tests that are judged by the&#xD;
             investigator to be clinically significant.&#xD;
&#xD;
         18. Not suitable for this study as determined by the investigator due to other reasons.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Wuhan Medical Treatment Center</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430040</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 7, 2021</study_first_submitted>
  <study_first_submitted_qc>July 28, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 6, 2021</study_first_posted>
  <last_update_submitted>July 28, 2021</last_update_submitted>
  <last_update_submitted_qc>July 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amphotericin B</mesh_term>
    <mesh_term>Liposomal amphotericin B</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

